Genetic evidence for a normal-weight "metabolically obese" phenotype linking insulin resistance, hypertension, coronary artery disease, and type 2 diabetes - PubMed (original) (raw)

. 2014 Dec;63(12):4369-77.

doi: 10.2337/db14-0318. Epub 2014 Jul 21.

Robert A Scott 2, Charles C White 3, Weihua Zhang 4, Elizabeth Speliotes 5, Patricia B Munroe 6, Georg B Ehret 7, Joshua C Bis 8, Caroline S Fox 9, Mark Walker 10, Ingrid B Borecki 11, Joshua W Knowles 12, Laura Yerges-Armstrong 13, Claes Ohlsson 14, John R B Perry 2, John C Chambers 4, Jaspal S Kooner 15, Nora Franceschini 16, Claudia Langenberg 17, Marie-France Hivert 18, Zari Dastani 19, J Brent Richards 20, Robert K Semple 21, Timothy M Frayling 22

Affiliations

Genetic evidence for a normal-weight "metabolically obese" phenotype linking insulin resistance, hypertension, coronary artery disease, and type 2 diabetes

Hanieh Yaghootkar et al. Diabetes. 2014 Dec.

Abstract

The mechanisms that predispose to hypertension, coronary artery disease (CAD), and type 2 diabetes (T2D) in individuals of normal weight are poorly understood. In contrast, in monogenic primary lipodystrophy-a reduction in subcutaneous adipose tissue-it is clear that it is adipose dysfunction that causes severe insulin resistance (IR), hypertension, CAD, and T2D. We aimed to test the hypothesis that common alleles associated with IR also influence the wider clinical and biochemical profile of monogenic IR. We selected 19 common genetic variants associated with fasting insulin-based measures of IR. We used hierarchical clustering and results from genome-wide association studies of eight nondisease outcomes of monogenic IR to group these variants. We analyzed genetic risk scores against disease outcomes, including 12,171 T2D cases, 40,365 CAD cases, and 69,828 individuals with blood pressure measurements. Hierarchical clustering identified 11 variants associated with a metabolic profile consistent with a common, subtle form of lipodystrophy. A genetic risk score consisting of these 11 IR risk alleles was associated with higher triglycerides (β = 0.018; P = 4 × 10(-29)), lower HDL cholesterol (β = -0.020; P = 7 × 10(-37)), greater hepatic steatosis (β = 0.021; P = 3 × 10(-4)), higher alanine transaminase (β = 0.002; P = 3 × 10(-5)), lower sex-hormone-binding globulin (β = -0.010; P = 9 × 10(-13)), and lower adiponectin (β = -0.015; P = 2 × 10(-26)). The same risk alleles were associated with lower BMI (per-allele β = -0.008; P = 7 × 10(-8)) and increased visceral-to-subcutaneous adipose tissue ratio (β = -0.015; P = 6 × 10(-7)). Individuals carrying ≥17 fasting insulin-raising alleles (5.5% population) were slimmer (0.30 kg/m(2)) but at increased risk of T2D (odds ratio [OR] 1.46; per-allele P = 5 × 10(-13)), CAD (OR 1.12; per-allele P = 1 × 10(-5)), and increased blood pressure (systolic and diastolic blood pressure of 1.21 mmHg [per-allele P = 2 × 10(-5)] and 0.67 mmHg [per-allele P = 2 × 10(-4)], respectively) compared with individuals carrying ≤9 risk alleles (5.5% population). Our results provide genetic evidence for a link between the three diseases of the "metabolic syndrome" and point to reduced subcutaneous adiposity as a central mechanism.

© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Cluster analysis of fasting insulin variants using eight traits known to be nondisease metabolic traits of monogenic IR, including those representing dyslipidemia (HDL and triglyceride), adiposity (BMI and visceral-to-subcutaneous adipose tissue ratio), fatty liver (CT-measured hepatic steatosis and the liver enzyme ALT), and adiponectin and SHBG levels. The dendrogram (A) shows that 11 variants and 5 variants are grouped in two significant clusters (the approximate unbiased values = 96% [P = 0.04] and 98% [P = 0.02], respectively). The heatmap (B) shows this cluster is consistent with monogenic lipodystrophic IR; the stronger the green color, the stronger the effect of the insulin-raising allele with reduced trait levels; the stronger the pink color, the stronger the effect of the insulin-raising allele with higher trait levels. VATSAT, visceral-to-subcutaneous adipose tissue ratio; NAFLD, nonalcoholic fatty liver disease.

Figure 2

Figure 2

Forest plots of the effect of the 11 “lipodystrophy-like” variants on six metabolic disease outcomes. The _x_-axis is the effect size per fasting insulin–increasing alleles on each trait. The dashed line is the null effect. For cIMT, actual effects ranged from −0.003 to 0.003 but here are shown rounded to two decimal places. FE, fixed effect.

Comment in

Similar articles

Cited by

References

    1. Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S. The metabolically obese, normal-weight individual revisited. Diabetes 1998;47:699–713 - PubMed
    1. Ruderman NB, Schneider SH, Berchtold P. The “metabolically-obese,” normal-weight individual. Am J Clin Nutr 1981;34:1617–1621 - PubMed
    1. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. 1988. Nutrition 1997;13:65; discussion 64, 66 - PubMed
    1. Semple RK, Savage DB, Cochran EK, Gorden P, O’Rahilly S. Genetic syndromes of severe insulin resistance. Endocr Rev 2011;32:498–514 - PubMed
    1. Semple RK, Chatterjee VK, O’Rahilly S. PPAR gamma and human metabolic disease. J Clin Invest 2006;116:581–589 - PMC - PubMed

Publication types

MeSH terms

Grants and funding

LinkOut - more resources